Jardiance recommended for the treatment of adults with chronic kidney disease in the EU.- Boehringer + Eli Lilly
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced ; Empagliflozin is currently indicated for the treatment of heart failure and type 2 diabetes in adults.
When approved, empagliflozin’s indications in the EU will include adults living with CKD, paving the way for an approach to managing the amplified risks of interconnected cardio-renal-metabolic conditions.
“EMPA-KIDNEY, the trial upon which the CHMP recommendation is based, demonstrated clear benefits on its primary outcome based on kidney disease progression and cardiovascular death in a broad range of adults with chronic kidney disease,” said Professor William Herrington, Clinician Scientist at the Medical Research Council Population Health Research Unit at the University of Oxford, UK, and EMPA-KIDNEY trial Co-Principal Investigator. “The approval of empagliflozin should greatly help implementation of these important findings into clinical practice for people living with chronic kidney disease,” added Co-Principal Investigator Professor Richard Haynes.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.